Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)

计划入组 150 人 · 首次发布于 2023 年 10 月 26 日

Genitourinary Tumors With Sacituzumab Tirumotecan

计划入组 100 人 · 首次发布于 2026 年 7 月 21 日

Description of the Population With Genitourinary Tumors and COVID-19

计划入组 410 人 · 首次发布于 2020 年 10 月 8 日

solid tumors therapy

CLK3 inhibitor (oral, solid tumors), Biosplice Therapeutics

CLK2 inhibitor (oral, solid tumors), Biosplice Therapeutics

NHS FIFE

United Kingdom

SHANGHAI MODERN PHARMACEUTICAL CO.,LTD.

China

BioLine Rx

Israel

EMA Accepts Marketing Authorization Application for Cevira, First-in-Class Photodynamic Therapy for Cervical Lesions

Genenta Reports 3-Year Survival in Glioblastoma Patients with Temferon Cell Therapy

FDA Approvals in 2024: Advancing Treatment Paradigms in Solid Tumors and Hematologic Malignancies